GlassScriptPhysician profile
Elisha P Tilton
NPI 1518189869
$4,207.72
in general payments reported to CMS, 2019-2025
22 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $92.31 · 2021: $42.49 · 2022: $524 · 2023: $2,723 · 2024: $218 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,345 · Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,345.00 |
| Food and Beverage | $832.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $2,639.24 | 2019-2025 | Susvimo, Vabysmo |
| Eyepoint US, INC. | $268.67 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $208.02 | 2022-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $161.95 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $144.35 | 2022-2023 | Eylea |
| Alimera Sciences, INC. | $112.89 | 2019-2024 | Iluvien, Yutiq |
| Allergan, INC. | $101.74 | 2019-2020 | |
| Abbvie INC. | $82.71 | 2023-2024 | Ozurdex |
| Astellas Pharma US INC | $81.67 | 2023-2024 | Izervay |
| Regeneron Healthcare Solutions, INC. | $68.33 | 2019-2025 | Eylea Hd |
| Biogen, INC. | $55.67 | 2022-2023 | |
| Rxsight INC | $54.85 | 2023-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Notal Vision, INC. | $37.06 | 2022 | |
| Optos, INC. | $37.05 | 2019-2021 | |
| Alcon Vision LLC | $32.82 | 2025 | Clareon |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27.24 | 2024 | Tepezza |
| Bausch & Lomb Americas INC. | $22.66 | 2022 | |
| Ani Pharmaceuticals, INC. | $21.55 | 2025 | Iluvien |
| Genentech USA, INC. | $20.02 | 2022 | |
| Iridex Corporation | $17.80 | 2019 | |
| Eyevance Pharmaceuticals LLC | $11.43 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisha Tilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.